T1	Treatment 54 65	Ocriplasmin
T2	Treatment 109 158	Microplasmin for Intravitreous Injection-Traction
T3	Treatment 241 269	vitreomacular adhesion (VMA)
T4	Treatment 449 473	intravitreal ocriplasmin
T5	Treatment 581 593	(NEI VFQ-25)
T6	Treatment 1298 1312	of ocriplasmin
T7	Treatment 1323 1360	or placebo-injected vehicle (placebo)
T8	Treatment 1362 1376	The NEI VFQ-25
T9	Treatment 1419 1440	following ocriplasmin
T10	Treatment 1521 1541	follow-up NEI VFQ-25
T11	Treatment 1707 1727	received ocriplasmin
T12	Treatment 1736 1752	received placebo
T13	Treatment 1841 1855	the NEI VFQ-25
T14	Treatment 1877 1888	the placebo
T15	Treatment 2042 2064	for the ocriplasmin vs
T16	Treatment 2286 2303	higher proportion
T17	Treatment 2466 2492	respectively; P = .03)
T18	Treatment 2570 2582	their visual
T19	Treatment 2703 2726	various subscale scores
T20	Treatment 2804 2811	day 28.
T21	Treatment 2812 2823	CONCLUSIONS
